Trial · NCT02915835
Trial comparisons16
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
1 to 16 of 16
Download this page as JSON| Comparison | Source |
|---|---|
| Riociguat vs Placebo: Proportion of Participants Who Develop Pressure Ulcers at Proximal Interphalangeal (PIP) Location Over the Course of the Double-blind Period. | Trial comparisons |
| Riociguat vs Placebo: Proportion of Participants With New Active and Indeterminate DU(s) Over the Course of the Double-blind Period | Trial comparisons |
| Riociguat vs Placebo: Proportion of Participants With Healing of Their Cardinal DU by Week 16 | Trial comparisons |
| Riociguat vs Placebo: Proportion of Participants Who Experience Digital Ischemia Requiring Intravenous Prostacyclin or Digital Gangrene or Amputation During the Trial. | Trial comparisons |
| Riociguat vs Placebo: Proportion of Participants Who Develop Pressure Ulcers at Distal Interphalangeal (DIP) Location Over the Course of the Double-blind Period. | Trial comparisons |
| Riociguat vs Placebo: Proportion of Participants With Healing of All Pressure Ulcers at the Elbows Over the Course of the Double-blind Period. | Trial comparisons |
| Riociguat vs Placebo: Proportion of Participants With Healing of All DUs at Baseline by Week 16 | Trial comparisons |
| Riociguat vs Placebo: Proportion of Participants With Healing of All Pressure Ulcers at the Proximal Interphalangeal (PIP) Over the Course of the Double-blind Period. | Trial comparisons |
| Riociguat vs Placebo: Proportion of Participants With no DUs at Week 16 | Trial comparisons |
| Riociguat vs Placebo: Proportion of Participants With Healing of All Pressure Ulcers at the Metacarpophalangeal (MCPs) Over the Course of the Double-blind Period. | Trial comparisons |
| Riociguat vs Placebo: Proportion of Participants Who Develop Pressure Ulcers at Metacarpophalangeal (MCPs) Location Over the Course of the Double-blind Period. | Trial comparisons |
| Riociguat vs Placebo: Proportion of Participants Who Develop Pressure Ulcers at the Elbows Over the Course of the Double-blind Period. | Trial comparisons |
| Riociguat vs Placebo: deaths from any cause | Trial comparisons |
| Riociguat vs Placebo: Proportion of Participants With Healing of All Pressure Ulcers at the Distal Interphalangeal (DIP) Over the Course of the Double-blind Period. | Trial comparisons |
| Riociguat vs Placebo: Proportion of Participants Who Develop Osteomyelitis During The Trial | Trial comparisons |
| Riociguat vs Placebo: serious adverse events | Trial comparisons |
trials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02915835/comparisons